Company news

INmune Bio Inc. news in 2026

INmune Bio Inc.'s news releases, calls and decks from 2026, newest first.

View company

INmune Bio Inc. Announces Third Quarter 2026 Results and Provides Business Update

November 5, 2026

INmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5th

October 29, 2026

INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement

October 28, 2026

INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027

October 21, 2026

INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar

October 21, 2026

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™

October 14, 2026

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro

October 14, 2026

INmune Bio to Attend the 2026 Maxim Growth Summit

October 6, 2026

INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board

September 14, 2026

INmune Bio to Present at the H.C. Wainwright Global Investment Conference

September 9, 2026

INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings

August 26, 2026

INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress

August 6, 2026

INmune Bio Receives R&D Rebates of Approximately $4.6 Million

July 31, 2026

INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th

July 31, 2026

INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform

July 30, 2026

INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform

July 20, 2026

INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study

July 15, 2026

INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC

July 9, 2026

INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion

July 1, 2026

INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom

June 26, 2026

INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™

June 25, 2026

INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB

June 23, 2026

INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial

June 1, 2026

INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform

May 15, 2026

INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease

May 13, 2026

INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point

May 12, 2026

INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update

May 7, 2026

INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases

May 5, 2026

INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th

April 30, 2026

INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models

April 15, 2026

INmune Bio Inc. Announces 2025 Results and Provides Business Update

March 29, 2026

INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.

March 23, 2026

INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease

March 18, 2026

INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar

February 23, 2026

INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB

February 19, 2026

INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease

February 12, 2026

INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB

February 10, 2026

INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives

January 27, 2026

Calls in 2026

Decks in 2026